Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 5/20 | 0.81 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86350 | 0.90 | AKR1B1 (0.77) | AKR1B1NOTUMMAPK14MAPTSMN1; SMN2 | |
| Tiopinac SCHEMBL38905 | 0.90 | AKR1B1 (1.00) | AKR1B1NOTUMMAPK14PARK7 | |
| SCHEMBL38906 | 0.87 | AKR1B1 (0.81) | AKR1B1NOTUMMAPK14 | |
| Tiopinac SCHEMBL11569336 | 0.83 | AKR1B1 (0.86) | AKR1B1MAPK14PARK7 | |
| SCHEMBL11569516 | 0.82 | AKR1B1 (0.73) | AKR1B1MAPT | |
| SCHEMBL11871739 | 0.81 | AKR1B1 (0.61) | AKR1B1MAPTSMN1; SMN2 | |
| SCHEMBL11876169 | 0.81 | AKR1B1 (0.61) | AKR1B1MAPT | |
| SCHEMBL11568863 | 0.80 | AKR1B1 (0.70) | AKR1B1 | |
| SCHEMBL11088738 | 0.79 | AKR1B1 (0.74) | AKR1B1MAPK14PARK7 | |
| SCHEMBL16091078 | 0.79 | AKR1B1 (0.67) | AKR1B1PARK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2053095-B1 | Ink composition and inkjet recording method using the same | FUJIFILM CORP (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8129447-B2 | Ink composition and inkjet recording method using the same | FUJIFILM CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129447-B2 | Ink composition and inkjet recording method using the same | FUJIFILM CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-2053095-A2 | Ink composition and inkjet recording method using the same | Fujifilm Corporation (JP) | 2009-04-29 | — | — | EP | disclosed |
| US-20090087575-A1 | INK COMPOSITION AND INKJET RECORDING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20090087575-A1 | INK COMPOSITION AND INKJET RECORDING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087575-A1 | INK COMPOSITION AND INKJET RECORDING METHOD USING THE SAME | RB1, IK, NOX1 | AKR1B1 1704/4885NOTUM 3865/4885MAPK14 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.